Update on the Diagnosis and Management of Wilson Disease
- 441 Downloads
Purpose of Review
Exciting developments relating to Wilson disease (WD) have taken place with respect to both basic biological and clinical research. This review critically examines some of these findings and considers their implications for current thinking about WD. It is not a comprehensive review of WD as a clinical disorder.
The structure of the gene product of ATP7B, abnormal in WD, is being worked out in detail, along with a broader description of how the protein ATP7B (Wilson ATPase) functions in cells including enterocytes, not only in relation to copper disposition but also to lipid synthesis. Recent population studies raise the possibility that WD displays incomplete penetrance. Innovative screening techniques may increase ascertainment. New strategies for diagnosing and treating WD are being developed. Several disorders have been identified which might qualify as WD-mimics.
WD can be difficult to diagnose and treat. Insights from its pathobiology are providing new options for managing WD.
KeywordsHepatolenticular degeneration Wilson disease ATP7B Wilson ATPase Copper Hepatic Neurological Psychiatric d-penicillamine Trientine Zinc salts Bis-choline tetrathiomolybdate Methanobactin Drug-pricing
Compliance with Ethical Standards
Conflict of Interest
Eve Roberts declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
- 4.• Mordaunt CE, Shibata NM, Kieffer DA, Czlonkowska A, Litwin T, Weiss KH, Gotthardt DN, et al. Epigenetic changes of the thioredoxin system in the tx-j mouse model and in patients with Wilson disease. Hum Mol Genet. 2018 Jul 16. Most recent report relating to epigenetic mechanisms in WD. Google Scholar
- 11.•• Muchenditsi A, Yang H, Hamilton JP, Koganti L, Housseau F, Aronov L, et al. Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice. Am J Physiol Gastrointest Liver Physiol. 2017;313:G39–49 Innovative, potentially important, new model for WD in mice. PubMedPubMedCentralGoogle Scholar
- 13.Carta MG, Farina GC, Sorbello O, Moro MF, Demelia E, Cadoni F, et al. The risk of bipolar disorders and major depressive disorders in Wilson’s disease: results of a case-control study (abstr.). Int Clin Psychopahramcol. 2012;e61:28.Google Scholar
- 31.•• Socha P, Janczyk W, Dhawan A, Baumann U, D'Antiga L, Tanner S, et al. Wilson’s disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:334–44 General overview of pediatric WD. PubMedGoogle Scholar
- 54.Ramraj R, Finegold MJ, Karpen SJ. Progressive familial intrahepatic cholestasis type 3: overlapping presentation with Wilson disease. Clin Pediatr (Phila). 2012;51:689–91.Google Scholar
- 76.• Chesi G, Hegde RN, Iacobacci S, Concilli M, Parashuraman S, Festa BP, et al. Identification of p38 MAPK and JNK as new targets for correction of Wilson disease-causing ATP7B mutants. Hepatology. 2016;63:1842–59 Possibility of rescuing some mutant versions of the Wilson ATPase. PubMedPubMedCentralGoogle Scholar
- 77.Hamilton JP, Koganti L, Muchenditsi A, Pendyala VS, Huso D, Hankin J, et al. Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7b −/− (Wilson Disease) (Wilson disease) mice. Hepatology. 2016;63:1828–41.Google Scholar
- 81.Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018.Google Scholar